Patents Assigned to Aleta Biotherapeutics Inc.
  • CD19 variants
    Patent number: 11891426
    Abstract: CD19 variants, methods of identifying CD19 variants, and methods of using such CD19 variants, e.g., for treating cancer, are described.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: February 6, 2024
    Assignees: Aleta Biotherapeutics Inc., Regents of The University of Minnesota
    Inventors: Roy Lobb, Paul Rennert, Benjamin Hackel, Justin Klesmith
  • Compositions and methods for treatment of cancer
    Patent number: 11807691
    Abstract: Compositions, e.g., compositions comprising cellular therapeutics and/or protein therapeutics, and methods of using such compositions for treating cancer are described.
    Type: Grant
    Filed: February 14, 2020
    Date of Patent: November 7, 2023
    Assignee: Aleta Biotherapeutics Inc.
    Inventors: Roy Lobb, Paul Rennert
  • SINGLE DOMAIN ANTIBODIES AGAINST CLL-1
    Publication number: 20220112292
    Abstract: Antibodies that specifically bind to CLL-1 are described, as well as methods of making and using such antibodies. In one aspect, the present disclosure provides, among other things, antibodies, or antigen binding fragments thereof, that bind (e.g., selectively bind) CLL-1, compositions useful for binding CLL-1, and methods for treating disease comprising administration of such antibodies, or antigen binding fragments thereof.
    Type: Application
    Filed: November 27, 2019
    Publication date: April 14, 2022
    Applicants: Aleta Biotherapeutics Inc., Aleta Biotherapeutics Inc.
    Inventors: Roy Lobb, Paul Rennert
  • Targeted cancer therapy
    Patent number: 11207339
    Abstract: Some embodiments of the present disclosure are directed to methods that include delivering to a subject a nucleic acid encoding an antigen, wherein the nucleic acid is delivered via a tumor-selective vehicle or via intratumoral injection, and delivering to the subject an immune cell expressing a receptor that binds to the antigen.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: December 28, 2021
    Assignees: The United States of America, as Represented by the Secretary, Department of Health and Human Services, Aleta Biotherapeutics Inc.
    Inventors: Roy Lobb, Paul David Rennert, John Todd Schiller
  • Compositions and methods for tumor transduction
    Patent number: 11059904
    Abstract: The invention relates to cancer therapeutics, in particular, the system of making cancer cells more susceptible to effector cells by introduction of cellular therapy targets into the cancer cells.
    Type: Grant
    Filed: August 1, 2018
    Date of Patent: July 13, 2021
    Assignee: Aleta Biotherapeutics Inc.
    Inventors: Roy Lobb, Paul Rennert
  • Compositions and methods for treatment of cancer
    Patent number: 10669349
    Abstract: Compositions, e.g., compositions comprising cellular therapeutics and/or protein therapeutics, and methods of using such compositions for treating cancer are described.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: June 2, 2020
    Assignee: Aleta Biotherapeutics Inc.
    Inventors: Roy Lobb, Paul Rennert
  • Compositions and methods for treatment of cancer
    Patent number: 10508143
    Abstract: Compositions, e.g., compositions comprising cellular therapeutics and/or protein therapeutics, and methods of using such compositions for treating cancer are described.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: December 17, 2019
    Assignee: Aleta Biotherapeutics Inc.
    Inventors: Roy Lobb, Paul Rennert
  • TARGETED CANCER THERAPY
    Publication number: 20180311374
    Abstract: Some embodiments of the present disclosure are directed to methods that include delivering to a subject a papillomavirus particle or soluble papillomavirus protein that targets a tumor, and delivering to the subject an immune cell expressing a receptor that binds to a surface antigen of the papillomavirus particle or soluble papillomavirus protein, respectively.
    Type: Application
    Filed: October 28, 2016
    Publication date: November 1, 2018
    Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Serv, Aleta Biotherapeutics, Inc.
    Inventors: Roy Lobb, Paul David Rennert, John Todd Schiller
  • TARGETED CANCER THERAPY
    Publication number: 20180311269
    Abstract: Some embodiments of the present disclosure are directed to methods that include delivering to a subject a nucleic acid encoding an antigen, wherein the nucleic acid is delivered via a tumor-selective vehicle or via intratumoral injection, and delivering to the subject an immune cell expressing a receptor that binds to the antigen.
    Type: Application
    Filed: October 28, 2016
    Publication date: November 1, 2018
    Applicants: The United States of America, as represented by the Secretary, Dept. of Health and Human Service, Aleta Biotherapeutics, Inc.
    Inventors: Roy Lobb, Paul David Rennert, John Todd Schiller
  • Compositions and methods for tumor transduction
    Patent number: 10072094
    Abstract: The invention relates to cancer therapeutics, in particular, the system of making cancer cells more susceptible to effector cells by introduction of cellular therapy targets into the cancer cells.
    Type: Grant
    Filed: August 7, 2017
    Date of Patent: September 11, 2018
    Assignee: Aleta Biotherapeutics Inc.
    Inventors: Roy Lobb, Paul Rennert
  • Compositions and methods for tumor transduction
    Patent number: 10066023
    Abstract: The invention relates to cancer therapeutics, in particular, the system of making cancer cells more susceptible to effector cells by introduction of cellular therapy targets into the cancer cells.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: September 4, 2018
    Assignee: Aleta Biotherapeutics Inc.
    Inventors: Roy Lobb, Paul Rennert